Johnson & Johnson reported positive results from the Phase 3b SPECTREM study on Tremfya for moderate plaque psoriasis, showing significant skin clearance and treatment outcomes. Tremfya achieved higher clearance rates compared to placebo across special sites, with improvements in secondary endpoints.